| Literature DB >> 34084550 |
Daim Asif Raja1, Fazeelah Munir1, Muhammad Raza Shah1, Muhammad Iqbal Bhanger1, Muhammad Imran Malik1,2.
Abstract
The development of metal nanoparticle-based facile colorimetric assays for drugs and insecticides is an emerging area of current scientific research. In the present work, polypropylene glycol was used for stabilization of gold nanoparticles (AuNPs) in a simple one-pot two-phase process and subsequently employed it for the specific detection of cephradine (CPH). The characterization of the prepared PPG-AuNPs was conducted through various analytical techniques such as UV-visible spectrophotometry, Fourier transform infrared spectroscopy, atomic force microscopy (AFM), zeta potential and zetasizer techniques. As the major target of the study, the stabilized PPG-AuNPs were employed for colorimetric detection of CPH and other drugs. Typical wine-red colour of PPG-AuNPs disappeared immediately and surface plasmon resonance band quenched by addition of CPH in the presence of several other interferents (drugs and salts) and in real samples. PPG-AuNPs permitted efficient, selective, reliable and rapid determination in a concentration range of 0.01-120 mM with a detection limit (LoD) of 11.0 mM. The developed sensor has the potential to be used for fast scanning of pharmaceutical formulations for quantification of CPH at production facilities.Entities:
Keywords: PPG-AuNPs; cephradine; colorimetric sensor; environmental and biological samples; polypropylene glycol
Year: 2021 PMID: 34084550 PMCID: PMC8150016 DOI: 10.1098/rsos.210185
Source DB: PubMed Journal: R Soc Open Sci ISSN: 2054-5703 Impact factor: 2.963
Figure 1(a) UV-visible spectra of PPG-AuNPs at the optimized ratio of PPG and HAuCl4 . 3H2O (1 : 15); (b) three-dimensional AFM image of PPG-AuNPs.
Figure 5Comparison of PPG-AuNPs before and after addition of CPH by (I) AFMs, (II) average size, (III) the zeta potential of (a) PPG-AuNPs; (b) PPG-AuNPs/CPH; d.nm (diameter in nanometre); PPG (0.1 mM): HAuCl4 ⋅ 3H2O (0.25 mM): NaBH4 (5.0 mM) = 1 : 15 : 0.1 (v/v); pH ∼ 5.
Figure 2Stability of PPG-AuNPs through UV-visible spectroscopy (a) before and after incubation at 100°C; (b) after adding different concentrations of NaCl; (c) at different pH. Some parts of figure reproduced with permission of Elsevier from [22].
Figure 3UV-visible spectra of PPG-AuNPs before and after addition of different drugs; inset show the colour change after addition of CEF and CPH. A part of figure is reproduced from [22] with permission of Elsevier.
Figure 4Structure of CPH and other tested drugs in this study.
Figure 6FTIR spectra of PPG, PPG-AuNPs, CPH and PPG-AuNPs/CPH.
Scheme 1Schematic representation of AuNPs formation through steric stabilization by the PPG and drug recognition (CPH) of PPG-AuNPs/CPH.
Figure 7(a) UV-Vis spectra of PPG-AuNPs after addition of the variable amount of CPH; (b) magnified version of figure 7a in a range of 0.12 to 0.162 absorbance; (c) absorbance intensity as a function of the concentration of CPH.
Figure 8Job plot for the binding ratio of PPG-AuNPs and CPH.
Figure 9UV-Vis spectra showing the effect of interfering drugs and salts on CPH detection by PPG-AuNPs.
Comparison of the analytical methods for the detection of CPH.
| method/materials | linear range | LoDa | LoD (mM)b | sample | remarks | ref. |
|---|---|---|---|---|---|---|
| zero-crossing derivative spectrophotometry | 2.0–56.0 µg ml−1 | 0.16 µg ml−1 | 0.00045 | saline physiological serum and physiological serum-containing glucose | conditions optimization, no interference study, complex statistical calculations required, no study in biological samples | [ |
| atomic absorption spectrometric determination | 5–70 µg ml−1 | 6.69 μg ml−1 | 0.01914 | drug samples | lengthy conditions optimization, cost intensive, required heavy instrumentation, no interference study, no study in environmental and biological samples, trained operators required | [ |
| electrochemical study of the degradation product | 10−7–10−6 mol l−1 | 0.5 × 10−7 mol l−1 | 0.00005 | CPH solution | instrument-based method, selective electrodes required, limited accuracy, no interference study, trained operators required, no study in environmental and biological samples | [ |
| fluorescent supramolecular tweezers | 0.1–5 µM | 1 µM | 0.001 | mixture of drugs | complicated protocol, proper laboratory setup required, expensive instruments required, condition optimization required, no study in environmental and biological samples | [ |
| capillary zone electrophoresis | 93.8–6255.6 mg ml−1 | 5.0 µg ml−1 | 0.01431 | mixture of drugs | tedious sample preparation, costly internal standards, long analysis time, optimization issues, proper laboratory setup and trained operators required | [ |
| spectrofluorimetric method | 0.1–5.0 μg ml−1 | 1.09 × 10–2 ± 3.64 × 10–3 μg ml−1 | 0.000028 | commercial formulations | optimization of conditions, sophisticated instrumentation, trained operators required, cost intensive method | [ |
| fluorosurfactant-capped gold nanoparticles | 2.0–10.0 mg ml−1 | 0.8 µg ml−1 | 0.00228 | pharmaceutical formulations | no study in environmental and biological samples, usage of costly reagents, no interference studies in presence of similar nature drugs and electrolytes | [ |
| high-performance liquid chromatographic method | 0.2 to 30.0 µg ml−1 | 0.2 µg ml−1 | 0.000572 | human plasma samples | exclusive instrumentation, trained operators, long analysis time, lengthy sample preparation, optimization issues, long analysis time, expensive standards required | [ |
| spectrophotometric/PPG-AuNPs method | 0.025–120 mM | 11.0 mM | 11.0 | pharmaceutical formulations, water, blood plasma, urine, serum | simple procedure, reasonable sensitivity, high selectivity, short analysis time, basic instrumentation, economical, on-spot visual indication, no pre-treatment of the sample | this method |
aLoD in the units as given in the reference.
bLoD unit converted to mM.
Figure 10Effect of addition of CPH on absorption band of PPG-AuNPs (a) tap water; (b) blood plasma; (c) urine; (d) serum.
Quantitative analysis of CPH containing commercial samples with regard to claimed content of CPH.
| sample | mass of drug (mg) | amount of CPH as obtained by different techniques (mg) | manufacturer claim CPH (mg) | ||
|---|---|---|---|---|---|
| UV-Vis at 254 nm | HPLC-UV | PPG-AuNPs | |||
| Velosef (500 mg), (GSK) | 590 ± 1 | 490 ± 2 | 495 ± 3 | 430 ± 2 | 500 |
| Velosef (250 mg), (GSK) | 295 ± 2 | 235 ± 1 | 240 ± 1 | 215 ± 1 | 250 |